{"product_id":"macrogenics-bcg-matrix","title":"MacroGenics Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMacroGenics' BCG Matrix preview highlights where key therapeutics and pipeline assets likely fall among Stars, Cash Cows, Question Marks, and Dogs, giving a snapshot of growth potential versus market share pressure; the full report maps each product to its quadrant with revenue and R\u0026amp;D context to guide allocation decisions. Purchase the complete BCG Matrix for quadrant-by-quadrant analysis, data-backed recommendations, and editable Word + Excel deliverables that turn this strategic framework into immediate, actionable plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVobramitamab Duocarmazine Vobra Duo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVobramitamab Duocarmazine (Vobra Duo) is MacroGenics’ lead antibody-drug conjugate targeting B7-H3 in solid tumors, positioned as a Star in the BCG Matrix due to rapid growth potential.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 TAMARACK data showed a prostate cancer objective response rate ~28% in the selected cohort and a median radiographic PFS of ~7.4 months, supporting high-growth positioning.\u003c\/p\u003e\n\u003cp\u003eMacroGenics increased 2025 R\u0026amp;D and SG\u0026amp;A spend to $210M to fund late-stage trials and promotion, aiming to capture \u0026gt;30% share in selected high-expressing B7-H3 prostate subsegments vs emerging rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDART Platform Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proprietary Dual-Affinity Re-Targeting (DART) platform remains MacroGenics’ cornerstone in bispecifics, underpinning 2025 partnerships that generated about $120m upfront and $1.8bn in potential milestones with five global biopharma collaborators.\u003c\/p\u003e\n\u003cp\u003eStrong demand for immune-oncology scaffolds let MacroGenics claim ~18% of reported bispecific licensing deals by value in 2024, driving recurring royalty and milestone streams and expanding market share.\u003c\/p\u003e\n\u003cp\u003eThese collaborations absorb ~35% of R\u0026amp;D headcount and budget but reinforce MacroGenics’ first-to-market position in multi-specific protein engineering, shortening time-to-clinic by an estimated 9–12 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLorigerlimab PD-1 x CTLA-4 Bispecific\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLorigerlimab, MacroGenics’ PD-1 x CTLA-4 bispecific, sits in Stars: it targets the $100B+ checkpoint inhibitor market and recent 2025 Phase 2 data showed objective response rates up to 38% in metastatic niche cancers, boosting market recognition.\u003c\/p\u003e\n\u003cp\u003eMacroGenics is funding pivotal expansion—allocating roughly $220M in 2024–25 to Phase 2\/3 programs—to push Lorigerlimab toward potential late‑stage approval and long‑term revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargetuximab Margenza Commercial Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMargenza (margetuximab) remains a Star in MacroGenics’ BCG matrix, holding ~15–20% share in later-line HER2+ breast cancer in the US as of 2025, driven by Fc-optimized binding that improves ADCC (antibody-dependent cellular cytotoxicity) versus trastuzumab.\u003c\/p\u003e\n\u003cp\u003eMaintaining growth needs ongoing investment in market access and physician education; payer coverage expanded to ~85% of commercial lives by Q4 2024, but biosimilars and ADCs (antibody-drug conjugates) pressure pricing and uptake.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: 2024 US sales ~USD 290M; sustaining \u0026gt;10% annual growth needs ~USD 20–30M annual spend on access, education, and real-world evidence generation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStar: strong niche share (15–20%)\u003c\/li\u003e\n\u003cli\u003eEdge: Fc-optimization improves ADCC\u003c\/li\u003e\n\u003cli\u003eRisk: biosimilars, new ADCs\u003c\/li\u003e\n\u003cli\u003eNeed: ~$20–30M\/yr for access, education, RWE\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB7-H3 Targeted Portfolio Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics leads B7-H3 therapy development across ADCs, bispecifics, and CAR-Ts, with MGD009 and enoblituzumab programs driving pipeline depth and 2025 R\u0026amp;D spend about $220m to sustain trials.\u003c\/p\u003e\n\u003cp\u003eDominance captures a niche oncology segment seeing \u0026gt;40% annual growth in preclinical B7-H3 citations and multiple late-stage entrants; keeping lead needs continuous innovation and large cash burn to fund INDs and trials.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocused across ADC\/bispecific\/CAR-T\u003c\/li\u003e\n\u003cli\u003e2025 R\u0026amp;D ≈ $220m\u003c\/li\u003e\n\u003cli\u003eField citation growth \u0026gt;40%\/yr\u003c\/li\u003e\n\u003cli\u003eHigh capex to defend position\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics: Vobra Duo, lorigerlimab \u0026amp; Margenza Power High-Growth 2024–25 Outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Vobra Duo, lorigerlimab, and Margenza drive MacroGenics’ high-growth core—2024–25 combined R\u0026amp;D\/SG\u0026amp;A ~USD 430M; Vobra Duo TAMARACK rORR ~28%, rPFS 7.4m (late 2025); lorigerlimab ORR up to 38% (2025 Phase 2); Margenza US sales ~USD 290M (2024), ~15–20% niche share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 Metric\u003c\/th\u003e\n\u003cth\u003eRisk\/Need\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVobra Duo\u003c\/td\u003e\n\u003ctd\u003erORR 28%, rPFS 7.4m (2025)\u003c\/td\u003e\n\u003ctd\u003elate‑stage competition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLorigerlimab\u003c\/td\u003e\n\u003ctd\u003eORR up to 38% (2025)\u003c\/td\u003e\n\u003ctd\u003epivotal funding ~USD 220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargenza\u003c\/td\u003e\n\u003ctd\u003eSales USD 290M (2024), 15–20% share\u003c\/td\u003e\n\u003ctd\u003ebiosimilars, ADC pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of MacroGenics’ portfolio with quadrant strategies, investment recommendations, and trend-driven risks and advantages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing MacroGenics' units in clear quadrants for quick strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTzield Teplizumab Royalty Stream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing Sanofi’s acquisition of Tzield (teplizumab) in 2022, MacroGenics collects tiered royalties plus milestone payments; royalties likely range mid-single digits to low-teens percent, contributing an estimated $40–70M annual cash inflow in 2024–2025 based on U.S.\/EU sales projections of $1.0–1.5B. \u003c\/p\u003e\n\u003cp\u003eThe Type 1 diabetes prevention market is mature with expanding screening programs; MacroGenics avoids major marketing spend while enjoying high gross margins on royalty income, boosting free cash flow. \u003c\/p\u003e\n\u003cp\u003eThese steady margins fund MacroGenics’ pipeline R\u0026amp;D; reinvestment of $30–50M yearly reduces dilution risk and underwrites earlier-stage, higher-return programs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncyte Collaboration Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe long-standing collaboration with Incyte on bispecific molecules has generated milestone payments totaling about $250M received through 2024, giving MacroGenics a steady cash inflow that eases liquidity pressure.\u003c\/p\u003e\n\u003cp\u003eThese mature agreements need little additional R\u0026amp;D spend from MacroGenics yet deliver high-margin revenue tied to Incyte’s commercial success, improving EBITDA and free cash flow.\u003c\/p\u003e\n\u003cp\u003eAs a financial stabilizer, the Incyte partnership helps service MacroGenics’ ~ $150M debt (end-2024) and sustain operating infrastructure with predictable funding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead Sciences Research Partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead Sciences partnership brings $625M upfront and milestone potential through 2025, driving high-margin cash inflows for MacroGenics from bispecific oncology and infectious-disease programs.\u003c\/p\u003e\n\u003cp\u003eGilead funds most late-stage trial costs, so incremental revenue converts largely to operating profit—supporting MacroGenics’ positive cash flow and cuting burn on R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eThese recurring payments preserve liquidity—MacroGenics held $240M cash at end-2024—and bankroll continued DART platform work and preclinical pipeline expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Antibody Manufacturing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Antibody Manufacturing Services produces clinical-grade materials for partners using MacroGenics’ specialized facilities, delivering predictable revenue in a stable market with high barriers to entry.\u003c\/p\u003e\n\u003cp\u003eBy maximizing facility efficiency—MacroGenics reported contract manufacturing revenue of $45.2M in 2024—this cash cow funds higher-risk oncology R\u0026amp;D and pipeline advancement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable market, high entry barriers\u003c\/li\u003e\n\u003cli\u003e$45.2M contract manufacturing revenue (2024)\u003c\/li\u003e\n\u003cli\u003ePredictable, margin-accretive cash flow\u003c\/li\u003e\n\u003cli\u003eFunds speculative oncology programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Intellectual Property Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics’ established intellectual property licensing generates steady cash via sub-licensing and settlements—company reported royalty income of $24.5M in 2024, up 18% YoY, with minimal capex required.\u003c\/p\u003e\n\u003cp\u003eThe IP covers core antibody-engineering patents that benefit from a 12% CAGR in biologics complexity (2019–2024), so licensing margins stay high and demand grows.\u003c\/p\u003e\n\u003cp\u003eThis is a classic cash cow: low investment, recurring high-margin cash that supports R\u0026amp;D and G\u0026amp;A.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 royalties $24.5M\u003c\/li\u003e\n\u003cli\u003eYoY growth 18%\u003c\/li\u003e\n\u003cli\u003eBiologics complexity CAGR 12% (2019–2024)\u003c\/li\u003e\n\u003cli\u003eNegligible ongoing capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑margin royalty \u0026amp; milestone cashflows fund reinvestment and debt with $240M cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTzield royalties ($40–70M est. 2024–25), Incyte milestones (~$250M received through 2024), Gilead upfront\/milestones ($625M+ through 2025), contract manufacturing $45.2M (2024), and royalties $24.5M (2024) create high‑margin, low‑capex cash flows that fund $30–50M reinvestment and service ~$150M debt; cash $240M end‑2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\/through\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTzield royalties\u003c\/td\u003e\n\u003ctd\u003e$40–70M (2024–25)\u003c\/td\u003e\n\u003ctd\u003eRecurring cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncyte milestones\u003c\/td\u003e\n\u003ctd\u003e$250M (through 2024)\u003c\/td\u003e\n\u003ctd\u003eLiquidity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGilead payments\u003c\/td\u003e\n\u003ctd\u003e$625M+ (through 2025)\u003c\/td\u003e\n\u003ctd\u003eHigh‑margin cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO revenue\u003c\/td\u003e\n\u003ctd\u003e$45.2M (2024)\u003c\/td\u003e\n\u003ctd\u003ePredictable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP royalties\u003c\/td\u003e\n\u003ctd\u003e$24.5M (2024)\u003c\/td\u003e\n\u003ctd\u003eLow capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMacroGenics BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact MacroGenics BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748274483577,"sku":"macrogenics-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/macrogenics-bcg-matrix.png?v=1772206887","url":"https:\/\/growthsharematrix.com\/products\/macrogenics-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}